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177 Management and outcomes following pneumothorax in cystic
ﬁbrosis patients
J. Gallagher1, D. Nazareth1, S.M.H. Kazmi1, K. Mohan1, J. Greenwood1,
M. Ledson1, M. Walshaw1. 1Liverpool Heart & Chest Hospital NHS Foundation
Trust, Adult CF Unit, Liverpool, United Kingdom
Objectives: Spontaneous pneumothorax (PTx) is a well recognised complication
in CF and is associated with recurrence and increased morbidity and mortality. To
inform future management, we looked at the treatment and outcome of PTx in CF
patients attending our large adult centre.
Method: We reviewed 64 episodes of spontaneous PTx in 28 CF patients (mean
FEV1 32% predicted [range 16−68%], 36% male), focussing on modalities of
treatment and ultimate outcomes.
Results: Immediate treatments are shown in the table. Nine patients (32%) sustained
bilateral PTx and 50% had ipsilateral recurrence (mean interval 4 months). Twenty
four have died (63% at 1 year, 80% at 2 years, median survival 7 months [0−68])
after ﬁrst PTx, with the remaining 4 alive at 6−34 months post PTx.
Conclusions: We have conﬁrmed that spontaneous PTx is a poor prognostic factor
in CF with poor survival rates and a recurrence or a contralateral PTx increases
mortality. A multidisciplinary approach towards the treatment modalities for the
management of recurrent or persistent PTx is essential when dealing with this
complication.
Pneumothorax treatment and outcomes
Episodes
(n)
Resolution
(%)
2nd line
treatment
Complications Late
recurrence
(%)
Observation 13 69 Chest drain 23%
Pleurodesis 8%
Nil 31
Chest Drain 23 52 Surgery 39% Death 17% 43
Pleurodesis
(talc/blood)
18 72 Surgery 11% Death 11% 39
Surgery 10 50 NA Death 50% 20
178 Prognostic impact of recurrent pneumothoraces in adults with
cystic ﬁbrosis
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Rationale: To identify risk factors and long-term outcomes associated with spon-
taneous pneumothorax in adults with cystic ﬁbrosis.
Methods: Consecutive adult CF subjects who experienced at least one spontaneous
pneumothorax at Cochin Hospital (Paris, France) were individually matched (1:3)
for age, gender and FEV1 with CF subjects who did not have pneumothorax.
Multivariate conditional logistic regression was used to identify independent factors
associated with pneumothorax. Transplant-free survival was analysed using Kaplan-
Meier analysis. Cox proportional hazards model were used to examine impact of
pneumothorax on survival.
Results: From 1995 to 2010, 51 subjects had pneumothorax: 29 subjects had
one pneumothorax and 22 had 2 pneumothoraces. These subjects were matched
with 125 CF subjects without pneumothorax. No risk factor for pneumothorax
was identiﬁed. Adult CF patient who experienced pneumothorax had shorter
transplant-free survival (p = 0.03; log rank test). However, this difference was
due to shorter transplant-free survival in subjects who had 2 pneumothoraces
(p = 0.004), whereas subjects who had only one pneumothorax had comparable
outcome compared to subjects without pneumothorax (p = 0.52). In Cox analysis,
pneumothorax was an independent predictor associated with shorter survival: 1
pneumothorax (HR 2.10; 95%CI 0.94–4.69; p = 0.07) and 2 pneumothoraces
(HR 5.35; 95%CI 2.31–12.37; p< 0.0001).
Conclusion: No risk factor for pneumothorax was identiﬁed. Recurrent pneumoth-
oraces are associated with a major decrease of transplant-free survival, whereas
single occurrence of pneumothorax has little effect on survival.
179 Lung transplantation in cystic ﬁbrosis: waiting list results
L. Fila1, L. Valentova Bartakova1, V. Vavrova2, R. Lischke3. 1University Hospital
Motol, Pulmonary Department, Prague, Czech Republic; 2Charles University,
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Objectives: Lung transplantation (LuTx) is a treatment possibility in advanced
pulmonary diseases including cystic ﬁbrosis (CF). Careful evaluation of patients
before inclusion on waiting list (WL) is based on international guidelines (Orens JB
2006). Care for patients on WL includes regular evaluation of compensation of
underlying disease and comorbidities together with assessment of urgency, ability
to tolerate and proﬁt from LuTx. In this paper, we present single-centre experience
with results in patients included on WL for LuTx.
Methods: During 1998–2011 period, 44 CF patients (22 M, 22 F) were included
on WL for LuTx in Prague Transplant Center, Czech Republic (one woman twice,
because of the need for re-LuTx). Colonization of airways included Pseudomonas
aeruginosa in 23, Stenotrophomonas maltophilia in 3 and Burkholderia cepacia
complex/B. spec. in 12 cases; remaining patients were without these Gram-
negatives. Median (range) age at time on inclusion on WL was 24.6 (12.7–47.5)
years. Median (range) time on WL was 0.58 (0.03–2.37) years. 29 patients under-
went LuTx with median (range) time on WL 0.31 (0.03–2.37) years, 10 patients
died with median (range) time on WL 0.90 (0.10–2.16) years and 3 patiens were
removed from WL (colonization with B. cenocepacia ST-32 and improvement of
lung function in 2 and 1 patient, respectively). Remaining patients (3) are still
on WL. Time on WL in deceased patients was longer then in those who were
transplanted, but the difference did not reach statistical signiﬁcance (p = 0.19, Cox-
Mantel test). Mortality on WL was 22.2%.
Conclusions: LuTx is a viable treatment option in CF patients and increasing donor
pool may reduce WL mortality and shorten WL time.
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Objectives: Cystic Fibrosis (CF) patients experience frequent pulmonary exacerba-
tions (PExs). Clinicians manage these episodes of worsening signs and symptoms in
a variety of ways, but commonly with antibiotic treatment. A better understanding
of why clinicians choose IV vs. non-IV routes for antibiotic delivery may aid in
better deﬁning an exacerbation and improving therapy.
Methods:We used data from the Epidemiologic Study of CF to examine the patient
characteristics and choice of IV vs. non-IV antibiotics to treat PExs between 2003
and 2005. 45,374 PExs were reported in 13,194 unique patients. 39% of PExs
were treated with IV, 15% were treated with inhaled ± oral, and the remainder
received only oral antibiotics. The likelihood of non-IV vs. IV antibiotic treatment
was inﬂuenced by the patient’s age, stage of lung disease, and magnitude of lung
function drop prior to the PEx.
Conclusion: Clinicians treat the majority of PExs with oral antibiotics, particularly
in younger, healthier patients.
